In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Penelope MacRae

Advertisement
Set Alert for Articles By Penelope MacRae

Latest From Penelope MacRae

Magellan Rx Pushes For Switching To Oncology Biosimilars

Magellan Rx has launched a program to encourage a shift to lower-cost oncology biosimilars, ahead of their US market entry this year, building on what the PBM says has been a successful drive for some autoimmune conditions to be treated with biosimilar versions of infliximab.

Regulation Biosimilars

Sun’s Ilumya Set For Phase III In Psoriatic Arthritis After ‘Promising’ Results

Sun releases what it says are promising interim data from a Phase II study on Ilumya, its flagship first novel biologic, in the additional indication of psoriatic arthritis, where the antibody met the primary endpoint in its first trial in this setting.

Clinical Trials Business Strategies

Oklahoma Judge Wants More Details On Teva’s Opioid Settlement

An Oklahoma judge is withholding approval of the state’s proposed $85m out-of-court opioid settlement with Teva until he gets assurances that it complies with state law.

Legal Issues United States

Three Firms In Race For India’s Bankrupt Orchid Pharma

Three companies are in the race to take over bankrupt Orchid Pharmaceuticals under a new round of bidding being held for the generic drugmaker after a previous takeover deal collapsed.

Deals Strategy

Analysts See More Headwinds For India’s Zydus Cadila After Quarterly Earnings Slide

Analysts said more challenges lie ahead for Zydus Cadila that will hobble earnings growth over the next couple of years, after the Indian firm reported a more than 20% slide in quarterly profit.

Strategy Sales & Earnings

Aurobindo Upbeat On Outlook As It Moves To Close Sandoz Deal

India's Aurobindo says it is betting its $1bn purchase of Sandoz' US dermatology assets will help “really fuel growth” and that the company's biggest acquisition should be wrapped up in eight to 12 weeks.

Commercial Companies
See All
Advertisement
UsernamePublicRestriction

Register